Compare Occidental Petroleum Corporation (OXY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs TransMedics Group Inc — how do they compare? Occidental Petroleum Corporation trades at $60.03 (market cap $60.26B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Occidental Petroleum Corporation is far larger — about 22× TransMedics Group Inc's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and TransMedics Group Inc for 24 Days on average.
| OXY | TMDX | |
|---|---|---|
Market Cap | $60.26B | $2.74B |
Volume | 11,718,920 | 949,331 |
Sector | Energy | Health |
52-Week High | $66.24 | $150.42 |
52-Week Low | $38.92 | $61.99 |
Typical Hold Time | 92 Days | 24 Days |
Enterprise Value | $79.02B | $3.13B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.52, up 3.97% in the last session, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.40 surpassing the $1.83 expectation. Financial health is supported by a strong net income margin of 30.32% and an ROE of 21.46%, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is a Buy with a $71.40 price target, and a dividend of $0.28 is scheduled for payment in October 2026.
OXY presents a positive outlook driven by earnings beats, debt reduction efforts, and analyst optimism, but faces risks from volatile oil prices and declining revenue trends. Investment appeal hinges on execution of cash flow targets and oil market stability, with current valuation metrics like a P/E of 17.78 appearing reasonable relative to growth prospects.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
